Joint Bone Spine. 2006 Dec;73(6):606-9. Epub 2006 Oct 11.

Symptomatic slow-acting drugs for osteoarthritis: what are the facts?

Source

Rheumatology Department, Cochin Teaching Hospital, School of Medicine, Paris-Descartes University, Assistance Publique-Hôpitaux de Paris, 27, rue du Faubourg Saint-Jacques, 75014 Paris, France. m.doug@cch.aphp.fr

Abstract

The term "symptomatic slow-acting drugs for osteoarthritis" (SySADOA) was coined more than a decade ago to designate medications and/or nutritional supplements used to alleviate the manifestations of osteoarthritis in the long-term. Their efficacy has always been a focus of considerable skepticism. However, a critical reappraisal of the available data, which include results of carefully designed clinical trials conducted in accordance with Good Clinical Practice guidelines, strongly suggests a therapeutic effect. The effects of SySADOA need to be determined based, in particular, on treatment objectives (symptom relief, decreased use of nonsteroidal antiinflammatory drugs and other conventional agents, decreased radiographic progression, and decreased use of joint replacement surgery). In addition, the characteristics of the patients who are most likely to benefit from SySADOA need to be identified.

PMID:: 17126058; [PubMed - indexed for MEDLINE]

Publication Types, MeSH Terms, Substances

Publication Types

Review

MeSH Terms

Substances

LinkOut - more resources

Full Text Sources

Other Literature Sources

Labome Researcher Resource - ExactAntigen/Labome

Medical

Supplemental Content

Related citations

Review Clinical review of chondroitin sulfate in osteoarthritis. [Osteoarthritis Cartilage. 2008]
Review Clinical review of chondroitin sulfate in osteoarthritis.
Uebelhart D. Osteoarthritis Cartilage. 2008; 16 Suppl 3:S19-21. Epub 2008 Jul 31.
Review The pathobiology of osteoarthritis and the rationale for using the chondroitin sulfate for its treatment. [Curr Drug Targets Immune Endocr Metabol Dis...]
Review The pathobiology of osteoarthritis and the rationale for using the chondroitin sulfate for its treatment.
Volpi N. Curr Drug Targets Immune Endocr Metabol Disord. 2004 Jun; 4(2):119-27.
[Pharmacological treatment of osteoarthritis. Expectations and reality]. [Rev Clin Esp. 2005]
[Pharmacological treatment of osteoarthritis. Expectations and reality].
Mulero Mendoza J. Rev Clin Esp. 2005 Apr; 205(4):168-71.
Review [Assessment of the placebo effect of symptomatic slow-acting anti-arthritics]. [Presse Med. 1998]
Review [Assessment of the placebo effect of symptomatic slow-acting anti-arthritics].
Villani P, Bouvenot G. Presse Med. 1998 Feb 7; 27(5):211-4.
Review Chondroitin sulphate for symptomatic osteoarthritis: critical appraisal of meta-analyses. [Curr Med Res Opin. 2008]
Review Chondroitin sulphate for symptomatic osteoarthritis: critical appraisal of meta-analyses.
Monfort J, Martel-Pelletier J, Pelletier JP. Curr Med Res Opin. 2008 May; 24(5):1303-8. Epub 2008 Apr 15.

See reviews... See all...

Cited by 2 PubMed Central articles

A 40-month multicentre, randomised placebo-controlled study to assess the efficacy and carry-over effect of repeated intra-articular injections of hyaluronic acid in knee osteoarthritis: the AMELIA project. [Ann Rheum Dis. 2011]
A 40-month multicentre, randomised placebo-controlled study to assess the efficacy and carry-over effect of repeated intra-articular injections of hyaluronic acid in knee osteoarthritis: the AMELIA project.
Navarro-Sarabia F, Coronel P, Collantes E, Navarro FJ, de la Serna AR, Naranjo A, Gimeno M, Herrero-Beaumont G, AMELIA study group. Ann Rheum Dis. 2011 Nov; 70(11):1957-62. Epub 2011 Aug 17.
Protective effects of total fraction of avocado/soybean unsaponifiables on the structural changes in experimental dog osteoarthritis: inhibition of nitric oxide synthase and matrix metalloproteinase-13. [Arthritis Res Ther. 2009]
Protective effects of total fraction of avocado/soybean unsaponifiables on the structural changes in experimental dog osteoarthritis: inhibition of nitric oxide synthase and matrix metalloproteinase-13.
Boileau C, Martel-Pelletier J, Caron J, Msika P, Guillou GB, Baudouin C, Pelletier JP. Arthritis Res Ther. 2009; 11(2):R41. Epub 2009 Mar 16.

Chemical compound information

Chondroitin Sulfates

MW: 463.36 g/mol

MF: C₁₃H₂₁NO₁₅S

Related information

Related Citations
Calculated set of PubMed citations closely related to the selected article(s) retrieved using a word weight algorithm. Related articles are displayed in ranked order from most to least relevant, with the “linked from” citation displayed first.
Compound (MeSH Keyword)
PubChem chemical compound records that are classified under the same Medical Subject Headings (MeSH) controlled vocabulary as the current articles.
Substance (MeSH Keyword)
PubChem chemical substance (submitted) records that are classified under the same Medical Subject Headings (MeSH) controlled vocabulary as the current articles.
Cited in PMC
Full-text articles in the PubMed Central Database that cite the current articles.

Recent activity

Clear Turn Off Turn On

Symptomatic slow-acting drugs for osteoarthritis: what are the facts?
Symptomatic slow-acting drugs for osteoarthritis: what are the facts?
Joint Bone Spine. 2006 Dec ;73(6):606-9. Epub 2006 Oct 11 .

PubMed
The right to know belatedly comes to the health care system.
The right to know belatedly comes to the health care system.
Internist. 1989 Oct ;30(9):12-4.

PubMed
Codeine
Codeine

PubMed Health
The gut-brain barrier in major depression: intestinal mucosal dysfunction with a...
The gut-brain barrier in major depression: intestinal mucosal dysfunction with an increased translocation of LPS from gram negative enterobacteria (leaky gut) plays a role in the inflammatory pathophysiology of depression.
Neuro Endocrinol Lett. 2008 Feb ;29(1):117-24.

PubMed
Giant tonsillolith: report of a case.
Giant tonsillolith: report of a case.
Med Oral Patol Oral Cir Bucal. 2005 May-Jul ;10(3):239-42.

PubMed

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

PubMed

Display Settings:

Send to: